Wall Street brokerages expect that INmune Bio Inc (NASDAQ:INMB) will post earnings of ($0.19) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for INmune Bio’s earnings. The company is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that INmune Bio will report full year earnings of ($0.76) per share for the current fiscal year. For the next year, analysts expect that the company will post earnings of ($0.75) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that cover INmune Bio.

Separately, Maxim Group began coverage on INmune Bio in a research note on Tuesday, March 19th. They issued a “buy” rating and a $13.00 target price on the stock.

In related news, CFO David J. Moss bought 5,000 shares of the business’s stock in a transaction on Monday, May 6th. The shares were bought at an average price of $9.00 per share, for a total transaction of $45,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Raymond Joseph Tesi bought 11,100 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was bought at an average price of $9.90 per share, for a total transaction of $109,890.00. The disclosure for this purchase can be found here. Insiders acquired 77,767 shares of company stock worth $709,893 in the last quarter.

INMB traded down $0.13 on Wednesday, hitting $10.86. The company had a trading volume of 14,578 shares, compared to its average volume of 16,501. INmune Bio has a 12-month low of $7.00 and a 12-month high of $11.25.

INmune Bio Company Profile

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Read More: What are gap-down stocks?

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.